Abstract
Previous chapters have presented the robust theoretical case for EDA in comparison with current ways of analyzing API mass distribution profiles from OIPs. This chapter is in two distinct parts; the first part examines from the theoretical standpoint, ways in which changes in APSD could potentially go undetected by EDA; the second presents a series of case studies with a variety of OIP types that demonstrate the appropriateness of EDA as a powerful, yet simple-to-use tool for in vitro assessment of CI data. Discussion of theoretical failure modes is presented for general awareness. In a given product/method development, each sponsor would have to conduct their own analysis of potential failure modes based on their situation. Similarly, the case studies are presented as illustrations of EDA and AIM applications for several real OIPs. Each sponsor may develop a different way to implement AIM and EDA, depending on their purpose.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tougas TP, Christopher D, Mitchell JP, Strickland H, Wyka B, Van Oort M, Lyapustina S (2009) Improved quality control metrics for cascade impaction measurements of orally inhaled drug products (OIPs). AAPS PharmSciTechnol 10(4):1276–1285
Christopher D, Adams W, Amann A, Bertha C, Byron PR, Doub W, Dunbar C, Hauck W, Lyapustina S, Mitchell JP, Morgan B, Nichols S, Pan Z, Singh GPJ, Tougas T, Tsong Y, Wolff R, Wyka B (2007) Product quality research institute evaluation of cascade impactor profiles of pharmaceutical aerosols: Part 3 – Final report on a statistical procedure for determining equivalence. AAPS PharmSciTechnol 8(4):article 90. http://www.aapspharmscitech.org/view.asp?art=pt0804090. Accessed 10 Jan 2012
Mitchell JP, Christopher JD, Tougas T, Glaab V, Lyapustina S (2011) When could efficient data analysis (EDA) fail? Theoretical considerations. In: Dalby RN, Byron PR, Peart J, Suman JD, Young PM (eds) Respiratory drug delivery 2012. Davis Healthcare International, River Grove, IL, pp 237–245
Stein SW, Gabrio BJ (2000) Understanding throat deposition during cascade impactor testing. In: Dalby RN, Byron PR, Farr SJ, Peart J (eds) Respiratory drug delivery VII. Serentec, Raleigh, NC, pp 573–576
Sethuraman VV, Hickey AJ (2001) Evaluation of pre-separator performance for the 8-stage nonviable Andersen impactor. AAPS PharmSciTech 2(1):article 4. http://www.aapspharmscitech.org/. Accessed 11 Jan 2012
Mitchell JP, Nagel MW (2003) Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. J Aerosol Med 16(4):341–377
Pedersen S, Dubus JC, Crompton G (2010) The ADMIT series—issues in inhalation therapy 5: inhaler selection in children with asthma. Prim Care Resp J 19(3):209–216
Roller CM, Zhang G, Troedson RG, Leach CL, Le Souëf PN, Devadason SG (2007) Spacer inhalation technique and deposition of extrafine aerosol in asthmatic children. Eur Respir J 29(2):299–306
Glaab V, Goodey A, Lyapustina S, Mitchell J (2011) Efficient data analysis for MDIs and DPIs: failure mode effect analysis. In: Dalby RN, Byron PR, Peart J, Suman JD, Young PM (eds) Respiratory drug delivery Europe 2011. Davis Healthcare International, River Grove, IL, pp 225–236
Mitchell JP, Tougas T, Christopher D, Bauer R, Church T, Dey M, Glaab V, Goodey A, Holmes S, Iley T, Lyapustina S, Patel R, Quiroz J, Russell-Graham D, Strickland H, Svensson M, Van Oort M, Wu Z (2010) Abbreviated impactor measurement (AIM) and efficient data analysis (EDA) concepts: a partnership for the assurance of oral inhaled product (OIP) quality. Inhalation 4(6):6–10
Mao L, Ponder D, Hughes A, White J, Glaab G, Mitchell J, Lyapustina S (2012) Efficient data analysis (EDA) case study I: pressurized metered dose inhalers (MDIs) containing a solution formulation. In: Dalby RN, Byron PR, Peart J, Suman JD, Young PM (eds) Respiratory drug delivery 2012. Davis Healthcare International, River Grove, IL, pp 441–446
Christopher JD, Dey M (2011) Detecting differences in APSD: efficient data analysis (EDA) vs. stage groupings. In: Dalby RN, Byron PR, Peart J, Suman JD, Young PM (eds) Respiratory drug delivery Europe 2011. Davis Healthcare International, River Grove, IL, pp 215–223
Tougas TP, Christopher JD, Mitchell JP, Lyapustina S (2010) Efficient data analysis and abbreviated impactor measurement concepts. In: Dalby RN, Byron PR, Peart J, Suman JD, Young PM (eds) Respiratory drug delivery 2010. Davis Healthcare International, River Grove, IL, pp 599–603
Strickland H (2011) EDA and stage group metrics: can these metrics detect product changes. IPAC-RS conference “Bringing value to the patient in a changing world”, Rockville, MD, USA, Mar 2011, http://www.ipacrs.com/PDFs/IPAC-RS%202011%20Conference/AIM%20Workshop/6-CI%20Workshop%202011-Strickland.pdf. Accessed 11 Jan 2012
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Strickland, H. et al. (2013). Verification of the EDA Concept Through an Assessment of Theoretical Failure Modes, Failure Mode Analysis, and Case Studies with Real Data. In: Tougas, T., Mitchell, J., Lyapustina, S. (eds) Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-6296-5_9
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6296-5_9
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-6295-8
Online ISBN: 978-1-4614-6296-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)